Vision
Kinexus was incorporated at the end of the last millennium to realize the potential of systems biology approaches and transform the way signal transduction research is conducted.
With this aim, for over 26 years, Kinexus has striven to develop and offer an unrivalled suite of complementary proteomics and bioinformatics services to make signal transduction research easy, cost-effective and enabling for both academic and industrial scientists. We are pleased that we have been able to assist over 3500 researchers in 40 countries world-wide. In addition to our open-access, online knowledgebases and databases, over 450 peer-reviewed scientific publications have results from our scientists, collaborators and clients.
Research into cell signalling is extremely daunting due to its sheer complexity. At least 20% of the approximately 21,000 genes in the human genome encode cell signalling proteins. In the post-genomics world, one of the major challenges today is defining the potential interactions among these proteins and charting regulatory protein networks. Different cell and tissue types are strikingly distinct in their patterns of regulation of these important proteins. There appears to be an excess of over a million phosphorylation sites in the human phosphoproteome. Already about 250,000 human phosphosites have been experimentally confirmed. These phosphosites are likely to prove to be a rich source of biomarkers for disease detection. The over 536 protein kinases that catalyze their phosphorylation represent important drug targets for the pharmaceutical industry. Kinexus is dedicated to the longer-term prospect of defining new diagnostic tools and developing therapeutics to treat disease.
Kinexus has expanded its proteomics services to permit more customized work for our clients. This includes the launch of custom microarrays, peptide synthesis, protein production and mass spectrometry-based protein identification services. The offer of our Kinex™ antibody microarray and Kinetworks™ multi-immunoblotting services has been limited by the availability of high quality antibodies. Over 75% of the over 5,000 commercial antibodies that we have tested are impotent or non-specific. In the deployment of our proteomics services, in recent years, Kinexus has been undertaking the development of its own line of phosphorylation site and pan-specific antibodies. In addition, we are producing novel peptides as kinase substrates and inhibitors. Kinexus has now become a supplier of unique microarrays, antibodies and synthetic peptides to detect and assay signalling proteins.
To continue to develop innovative products and services, Kinexus has undertaken several important bioinformatics initiatives. We have generated over 10,000 Kinetworks™ multi-immunoblots in-house as well as 4,500 Kinex™ antibody microarray analyses to track the expression and phosphorylation of hundreds of protein kinases, phosphatases, transcription factors, cell cycle, stress and apopotosis proteins in thousands of different clinical samples, and tissue and cell lysates from animal experimental models. We have made a large portion of this immunoblotting and antibody microarray data freely available to the biomedical research community in our on-line KiNET-AM DataBank.
With this aim, for over 26 years, Kinexus has striven to develop and offer an unrivalled suite of complementary proteomics and bioinformatics services to make signal transduction research easy, cost-effective and enabling for both academic and industrial scientists. We are pleased that we have been able to assist over 3500 researchers in 40 countries world-wide. In addition to our open-access, online knowledgebases and databases, over 450 peer-reviewed scientific publications have results from our scientists, collaborators and clients.
Research into cell signalling is extremely daunting due to its sheer complexity. At least 20% of the approximately 21,000 genes in the human genome encode cell signalling proteins. In the post-genomics world, one of the major challenges today is defining the potential interactions among these proteins and charting regulatory protein networks. Different cell and tissue types are strikingly distinct in their patterns of regulation of these important proteins. There appears to be an excess of over a million phosphorylation sites in the human phosphoproteome. Already about 250,000 human phosphosites have been experimentally confirmed. These phosphosites are likely to prove to be a rich source of biomarkers for disease detection. The over 536 protein kinases that catalyze their phosphorylation represent important drug targets for the pharmaceutical industry. Kinexus is dedicated to the longer-term prospect of defining new diagnostic tools and developing therapeutics to treat disease.
Kinexus has expanded its proteomics services to permit more customized work for our clients. This includes the launch of custom microarrays, peptide synthesis, protein production and mass spectrometry-based protein identification services. The offer of our Kinex™ antibody microarray and Kinetworks™ multi-immunoblotting services has been limited by the availability of high quality antibodies. Over 75% of the over 5,000 commercial antibodies that we have tested are impotent or non-specific. In the deployment of our proteomics services, in recent years, Kinexus has been undertaking the development of its own line of phosphorylation site and pan-specific antibodies. In addition, we are producing novel peptides as kinase substrates and inhibitors. Kinexus has now become a supplier of unique microarrays, antibodies and synthetic peptides to detect and assay signalling proteins.
To continue to develop innovative products and services, Kinexus has undertaken several important bioinformatics initiatives. We have generated over 10,000 Kinetworks™ multi-immunoblots in-house as well as 4,500 Kinex™ antibody microarray analyses to track the expression and phosphorylation of hundreds of protein kinases, phosphatases, transcription factors, cell cycle, stress and apopotosis proteins in thousands of different clinical samples, and tissue and cell lysates from animal experimental models. We have made a large portion of this immunoblotting and antibody microarray data freely available to the biomedical research community in our on-line KiNET-AM DataBank.
In 2009, we launched the first of our on-line free access SigNET Knowledgebases called PhosphoNET, which tracks human phosphorylation sites. This website has been consistently updated since then, and joined over the years with additional knowledgebases for human protein kinases (KinaseNET), human cancer proteins (OncoNET), kinase inhibitory drugs (DrugKiNET), drug-protein interactions (DrugProNET) and human gene expression (TranscriptoNET). More recently, we launched the KinATLAS and KiNector websites that detail known kinase-substrate and signal transduction protein interactions in graphic maps. We plan to mine our databases and knowledgebases to continue to develop new antibodies and peptides to expand our line of proteomics services and products and further service the biomedical research community.
We remain fully committed to providing the highest standards of service and quality products possible for our clients. Over 93 percent of our clients have rated our services as good to excellent in the past. The integrity of the experimental results from our proteomics services is just as important to us as our customers. We consider our clients as our research partners, and we have been fortunate to have co-published scientific papers with several of our clients.
With the identification of the best therapeutic targets for oncology, diabetes and neurological diseases, Kinexus hopes to facilitate our clients in their development of novel inhibitors of selected protein kinases that can be used to manipulate signal transduction pathways for research and therapeutic purposes. One day, we shall be able to listen to cells by tapping into their communications systems to rapidly learn about the molecular lesions that underlie the most common diseases. We will exploit this information to silence these diseases by application of appropriate protein kinase inhibitors on an individual patient basis. It will be our greatest contributions to the development of personalized medicine, and it would have only been possible with the strong dedication of our employees, and the continuing support of our shareholders, clients, and collaborators.
Finally, one of our important objectives is to facilitate signal transduction research in the scientific community, in part by making our websites a major educational resource and portal for cell signalling information in the Internet. We very much welcome your suggestions as to how we can be of greatest value to you.
We remain fully committed to providing the highest standards of service and quality products possible for our clients. Over 93 percent of our clients have rated our services as good to excellent in the past. The integrity of the experimental results from our proteomics services is just as important to us as our customers. We consider our clients as our research partners, and we have been fortunate to have co-published scientific papers with several of our clients.
With the identification of the best therapeutic targets for oncology, diabetes and neurological diseases, Kinexus hopes to facilitate our clients in their development of novel inhibitors of selected protein kinases that can be used to manipulate signal transduction pathways for research and therapeutic purposes. One day, we shall be able to listen to cells by tapping into their communications systems to rapidly learn about the molecular lesions that underlie the most common diseases. We will exploit this information to silence these diseases by application of appropriate protein kinase inhibitors on an individual patient basis. It will be our greatest contributions to the development of personalized medicine, and it would have only been possible with the strong dedication of our employees, and the continuing support of our shareholders, clients, and collaborators.
Finally, one of our important objectives is to facilitate signal transduction research in the scientific community, in part by making our websites a major educational resource and portal for cell signalling information in the Internet. We very much welcome your suggestions as to how we can be of greatest value to you.
Sincerely,
Steven Pelech, Ph.D.
Founder, Director,
President & Chief Scientific Officer
December 1, 2025
Steven Pelech, Ph.D.
Founder, Director,
President & Chief Scientific Officer
December 1, 2025